• Tuberculosis and Respiratory Diseases
• /
• v.77 no.6
• /
• pp.274-278
• /
• 2014

Antiphospholipid syndrome (APS) is an acquired systemic autoimmune disorder characterized by a combination of clinical criteria, including vascular thrombosis or pregnancy morbidity and elevated antiphospholipid antibody titers. It is one of the causes of deep vein thrombosis and pulmonary embolism that can be critical due to the mortality risk. Overall recurrence of thromboembolism is very low with adequate anticoagulation prophylaxis. The most effective treatment to prevent recurrent thrombosis is long-term anticoagulation. We report on a 17-year-old male with APS, who manifested blue toe syndrome, deep vein thrombosis, pulmonary thromboembolism, and cerebral infarction despite adequate long-term anticoagulation therapy.

• Tuberculosis and Respiratory Diseases
• /
• v.64 no.1
• /
• pp.28-32
• /
• 2008

Pulmonary arterial thrombosis develops during hypercoagulable states, intra-arterial tumorous conditions, and congenital heart disease accompanied by pulmonary hypertension. Thrombosis in the main pulmonary arterial stump after pneumonectomy can also occur. Herein, we report a very rare case of pulmonary arterial thrombosis in a patient with pulmonary hypertension and a lung destroyed by tuberculosis. He presented with aggravated dyspnea without fever or purulent sputum. His chest computerized tomography scan showed left main pulmonary arterial thrombosis as a convex shape, with the ipsilateral distal arteries and arterioles showing parenchymal destruction. After excluding pulmonary thromboembolism and hypercoagulable disorders, we diagnosed pulmonary arterial thrombosis and treated him with an anticoagulant.

• Journal of Korean Medical classics
• /
• v.35 no.4
• /
• pp.63-75
• /
• 2022

Objectives : The purpose of this study is to examine the significance of Korean Medical literature on representative symptoms of postpartum deep venous thrombosis (DVT), such as lower extremity edema and pulmonary embolism. Methods : Pattern differentiation, cause, symptoms and treatment related to DVT and pulmonary embolism as written in Korean Medical texts were studied comparatively. Results : In Korean Medical understanding, DVT could be linked to lower extremity edema due to blood stagnation, while pulmonary embolism could be linked to coughing, asthma and nose bleed due to stagnated blood. Conclusions : To prevent relapse and manage its after-effects, Korean Medical treatment for DVT and pulmonary embolism is much in need.

• The Journal of Korean Medicine
• /
• v.25 no.1
• /
• pp.21-30
• /
• 2004

Objectives : We aimed to identify the effects of Heechum-san(HCS) On the thrombosis. Methods : We measured the protective effects of HCS on pulmonary thromboembolism induced by collagen and epinephrine, intravascular coagulation induced by dextran. Results : HCS showed a effective inhibition on coagulation of platelets induced by ADP or epinephrine. HCS showed survival rate of 14.28% on pulmonary thrombo- embolism caused by collagen and epinephrine. On the measure of the blood flow rate induced by the thrombus, in vivo HCS accelerated the blood flow rate. Conclusions : HCS has antithrombotic effects.

• Journal of Chest Surgery
• /
• v.23 no.4
• /
• pp.804-810
• /
• 1990

Pulmonary thromboembolism originated mostly from the venous thrombus, especially deep vein thrombosis in the lower extremities, which migrated upward and lodged the pulmonary vasculatures, Massive pulmonary thromboembolism usually leads to in \ulcornerhospital mortality if the patient was not treated properly. Under the cardiopulmonary bypass, a 49-year old man was treated successfully by emergent pulmonary embolectomy of pulmonary thromboembolism, which originated from the deep vein thrombosis in the right leg. Ligation or filtering device insertion of the inferior vena cava was not performed. The patient’s postoperative course was uneventful and discharged on postoperative 15th day He continued to receive oral anticoagulation with aspirin and persantin, which had been started on the third postoperative day. And he was well till recent days through the outpatient follow-up. The clinical courses of this patient are described, and massive pulmonary embolism and its management are discussed.

• Tuberculosis and Respiratory Diseases
• /
• v.73 no.4
• /
• pp.231-233
• /
• 2012

Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.

• Journal of Chest Surgery
• /
• v.46 no.1
• /
• pp.76-79
• /
• 2013

Venous aneurysms are uncommon in the lower limb and are more frequently found in the neck and thoracic and visceral veins. However, they have been reported to cause thrombosis, pulmonary thromboembolism, and other related complications. Popliteal venous aneurysms are often undetected because they are usually asymptomatic, but they may cause pulmonary thromboembolic events. We experienced a case of a 44-year-old man who was referred for recurrent pulmonary thromboembolism. He showed no other symptoms or signs except shortness of breath. A popliteal venous aneurysm was diagnosed incidentally because the examinations were performed to detect a deep vein thrombosis in relationship to the patient's history of pulmonary thromboembolism. We report a case of surgical treatment for a popliteal venous aneurysm that was complicated by pulmonary thromboembolism.

• Journal of the Korean Arthroscopy Society
• /
• v.10 no.1
• /
• pp.112-117
• /
• 2006

Deep vein thrombosis and pulmonary embolism are serious fatal complication after orthopedic surgery. Most of them occur after large operation such as total knee/hip arthroplasty. Some reports about deep vein thrombosis after simple arthroscopic procedure were on the Western literatures, but there was no report on the Korean literature. So we report two cases of pulmonary embolism after knee arthroscopic procedures.

• Tuberculosis and Respiratory Diseases
• /
• v.77 no.3
• /
• pp.105-110
• /
• 2014

Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is an important cause of morbidity and mortality. The aim of this review is to summarize the findings from clinically important publications over the last year in the area of VTE. In this review, we discuss 11 randomized controlled trials published from March 2013 to April 2014. The COAG and the EU-PACT trials indicate that pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or marginal usefulness in the Caucasian population. Recent clinical trials with novel oral anticoagulants (NOACs) have demonstrated that the efficacy and safety of rivaroxaban, apixaban, edoxaban, and dabigatran are not inferior to those of conventional anticoagulants for the treatment of VTE. The PEITHO and ULTIMA trials suggested that rescue thrombolysis or catheter-directed thrombolysis may maximize the clinical benefits and minimize the bleeding risk. Lastly, riociguat has a proven efficacy in treating chronic thromboembolic pulmonary hypertension. In the future, NOACs, riociguat, and catheter-directed thrombolysis have the potential to revolutionize the management of patients with VTE.

• Tuberculosis and Respiratory Diseases
• /
• v.71 no.4
• /
• pp.245-248
• /
• 2011

Venous thromboembolism represents as an obstruction of a vein by a blood clot in the blood stream. The most common manifestations of venous thromboembolism (VTE) are pulmonary embolism and deep vein thrombosis (DVT) of the lower extremity. This article reviews the recent advances in this spectrum and introduces new drugs that will be used in venous thromboembolism in the near future.